These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26260835)

  • 1. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1115-24, i-xv. PubMed ID: 26260835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
    Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
    PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis.
    Page AL; Ardizzoni E; Lassovsky M; Kirubi B; Bichkova D; Pedrotta A; Lastrucci C; de la Tour R; Bonnet M; Varaine F
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1078-83, i-iii. PubMed ID: 26260829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in distribution and use of tuberculosis diagnostic tests in Kenya: a cross-sectional survey.
    Oliwa JN; Maina J; Ayieko P; Gathara D; Kathure IA; Masini E; Van't Hoog AH; van Hensbroek MB; English M
    BMC Infect Dis; 2018 Jul; 18(1):328. PubMed ID: 30012092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model.
    Salje H; Andrews JR; Deo S; Satyanarayana S; Sun AY; Pai M; Dowdy DW
    PLoS Med; 2014 Jul; 11(7):e1001674. PubMed ID: 25025235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Kawkitinarong K; Suwanpimolkul G; Kateruttanakul P; Manosuthi W; Ubolyam S; Sophonphan J; Avihingsanon A; Ruxrungtham K
    Clin Infect Dis; 2017 May; 64(suppl_2):S171-S178. PubMed ID: 28475796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
    Raizada N; Sachdeva KS; Nair SA; Kulsange S; Gupta RS; Thakur R; Parmar M; Gray C; Ramachandran R; Vadera B; Ekka S; Dhawan S; Babre A; Ghedia M; Alavadi U; Dewan P; Khetrapal M; Khanna A; Boehme C; Paramsivan CN
    PLoS One; 2014; 9(8):e105346. PubMed ID: 25140877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.
    Raizada N; Sachdeva KS; Swaminathan S; Kulsange S; Khaparde SD; Nair SA; Khanna A; Chopra KK; Hanif M; Sethi GR; Umadevi KR; Keshav Chander G; Saha B; Shah A; Parmar M; Ghediya M; Jaju J; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(10):e0140375. PubMed ID: 26469691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
    Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
    Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
    Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
    Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre.
    Hodille E; Maisson A; Charlet L; Bauduin C; Genestet C; Fredenucci I; Rasigade JP; Lina G; Dumitrescu O
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):601-605. PubMed ID: 30680567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses.
    Kendall EA; Kamoga C; Kitonsa PJ; Nalutaaya A; Salvatore PP; Robsky K; Nakasolya O; Mukiibi J; Isooba D; Cattamanchi A; Kato-Maeda M; Katamba A; Dowdy DW
    PLoS One; 2019; 14(7):e0220251. PubMed ID: 31339935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.
    Naidoo P; Dunbar R; Lombard C; du Toit E; Caldwell J; Detjen A; Squire SB; Enarson DA; Beyers N
    PLoS One; 2016; 11(3):e0150487. PubMed ID: 26930400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.